In JoVE (2)
Other Publications (10)
- Journal of Molecular and Cellular Cardiology
- The American Journal of the Medical Sciences
- Tissue Engineering. Part A
- Geriatrics & Gerontology International
- Annals of Vascular Diseases
- Circulation Journal : Official Journal of the Japanese Circulation Society
- Rheumatology (Oxford, England)
- Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi
- Journal of Vascular Surgery
- Tissue Engineering. Part C, Methods
Articles by Shuhei Tara in JoVE
Fare Modeli Inferior Vena Cava İnterpozisyon Greft İmplantasyonu Yong-Ung Lee1, Tai Yi1, Shuhei Tara1, Avione Y. Lee1, Narutoshi Hibino1, Toshiharu Shinoka2, Christopher K. Breuer1,3 1Tissue Engineering Program and Surgical Research, Nationwide Children's Hospital, 2Department of Cardiothoracic Surgery, Nationwide Children's Hospital, 3Pediatric Surgery, Nationwide Children's Hospital Hücresel ve moleküler neotissue oluşumu hakkındaki bilgi geliştirmek için, TEVG bir fare modeli yakın zamanda geliştirilmiştir. Greftler C57BL / 6 farelerinde Infrarenal vena kava araya girme greft olarak implante edildi. Bu model bizim klinik araştırmada elde edilenlere benzer sonuçlar elde, ama çok kısaltılmış zaman zarfında.
Heterotopik Kalp Nakli bir Fare Modeli Kullanarak Pulmoner Vana Nakli Yong-Ung Lee1, Tai Yi1, Iyore James1, Shuhei Tara1, Alexander J. Stuber1, Kejal V. Shah1, Avione Y. Lee1, Tadahisa Sugiura1, Narutoshi Hibino2, Toshiharu Shinoka1, Christopher K. Breuer1,3 1Tissue Engineering Program and Surgical Research, Nationwide Children's Hospital, 2Cardiothoracic Surgery, Nationwide Children's Hospital, 3Pediatric Surgery, Nationwide Children's Hospital Doku mühendisliği kalp kapakçıklarında neotissue oluşumu ve darlık gelişimi altında yatan hücresel ve moleküler mekanizmaları anlamak için, heterotopik kalp kapakçığı nakli bir fare modeli geliştirilmiştir. Bir pulmoner kalp kapak heterotopik kalp nakli tekniği kullanılarak alıcıya nakil oldu.
Other articles by Shuhei Tara on PubMed
Transduction of the Anti-apoptotic PTD-FNK Protein Improves the Efficiency of Transplantation of Bone Marrow Mononuclear Cells Journal of Molecular and Cellular Cardiology. Mar, 2007 | Pubmed ID: 17229437 Since most transplanted cells rapidly die in an ischemic environment by hypoxia and hyponutrition, it is crucial to know how to protect transplanted cells for improving transplantation efficiency. We examined whether the transduction of an artificial anti-cell death protein (PTD-FNK) into bone marrow mononuclear cells (BM-MNCs) prevents cell death and improves the transplantation efficiency of BM-MNCs in ischemic regions. Rat bone marrow cells were prepared from the femur and tibia and cultured on dishes precoated with human fibronectin in the absence of serum. BM-MNCs transduced with PTD-FNK survived better than those without the protein (P
Therapeutic Angiogenesis by Controlled-release Fibroblast Growth Factor in a Patient with Churg-Strauss Syndrome Complicated by an Intractable Ischemic Leg Ulcer The American Journal of the Medical Sciences. Oct, 2009 | Pubmed ID: 19701077 Churg-Strauss syndrome (CSS) causes necrotizing vasculitis affecting small- to medium-sized arteries, mainly in the lungs, gastrointestinal system, heart, kidneys, and skin. Skin lesions sometimes ulcerate because of severe ischemia and become intractable when complicated by bacterial infection. We report a rare case of CSS, characterized by a nonhealing ischemic skin ulcer of the right calf with bacterial infection resistant to antibiotics. After sterile maggot debridement therapy, 2 skin autografts failed. Subsequently, a slow-release formula of basic fibroblast growth factor incorporated in biodegradable gelatin hydrogel was administered into the calf muscles to induce vascular regeneration. The ulcer eventually healed with no recurrence. This report describes the use of controlled-release basic fibroblast growth factor for an ischemic leg ulcer in a patient with CSS, suggesting a possible therapeutic role of this novel neovascularization therapy in treating severe skin lesions complicating autoimmune vasculitis syndromes.
Controlled-release Basic Fibroblast Growth Factor for Peripheral Artery Disease: Comparison with Autologous Bone Marrow-derived Stem Cell Transfer Tissue Engineering. Part A. Nov, 2011 | Pubmed ID: 21810028 We examined the safety and efficacy of controlled-release basic fibroblast growth factor (b-FGF) for peripheral artery disease (PAD), compared with autologous bone marrow mononuclear cell implantation (BMCI).
Prediction of Limb Salvage After Therapeutic Angiogenesis by Autologous Bone Marrow Cell Implantation in Patients with Critical Limb Ischemia Annals of Vascular Diseases. 2011 | Pubmed ID: 23555423 Purpose: Despite advances in therapeutic angiogenesis by bone marrow cell implantation (BMCI), limb amputation remains a major unfavorable outcome in patients with critical limb ischemia (CLI). We sought to identify predictor(s) of limb salvage in CLI patients who received BMCI. Materials and Methods: Nineteen patients with CLI who treated by BMCI were divided into two groups; four patients with above-the-ankle amputation by 12 weeks after BMCI (amputation group) and the remaining 15 patients without (salvage group). We performed several blood-flow examinations before BMCI. Ankle-brachial index (ABI) was measured with the standard method. Transcutaneous oxygen tension (TcPO2) was measured at the dorsum of the foot, in the absence (baseline) and presence (maximum TcPO2) of oxygen inhalation. (99m)technetium-tetrofosmin ((99m)Tc-TF) perfusion index was determined at the foot and lower leg as the ratio of brain. Results: Maximum TcPO2 (p = 0.031) and (99m)Tc-TF perfusion index in the foot (p = 0.0068) was significantly higher in the salvage group than in the amputation group. Receiver operating characteristic (ROC) curve analysis identified maximum TcPO2 and (99m)Tc-TF perfusion index in the foot as having high predictive accuracy for limb salvage. Conclusion: Maximum TcPO2 and (99m)Tc-TF perfusion index in the foot are promising predictors of limb salvage after BMCI in CLI.
Vessel Bioengineering Circulation Journal : Official Journal of the Japanese Circulation Society. Dec, 2013 | Pubmed ID: 24334558 The development of vascular bioengineering has led to a variety of novel treatment strategies for patients with cardiovascular disease. Notably, combining biodegradable scaffolds with autologous cell seeding to create tissue-engineered vascular grafts (TEVG) allows for in situ formation of organized neovascular tissue and we have demonstrated the clinical viability of this technique in patients with congenital heart defects. The role of the scaffold is to provide a temporary 3-dimensional structure for cells, but applying TEVG strategy to the arterial system requires scaffolds that can also endure arterial pressure. Both biodegradable synthetic polymers and extracellular matrix-based natural materials can be used to generate arterial scaffolds that satisfy these requirements. Furthermore, the role of specific cell types in tissue remodeling is crucial and as a result many different cell sources, from matured somatic cells to stem cells, are now used in a variety of arterial TEVG techniques. However, despite great progress in the field over the past decade, clinical effectiveness of small-diameter arterial TEVG (
Therapeutic Vascular Angiogenesis for Intractable Macroangiopathy-related Digital Ulcer in Patients with Systemic Sclerosis: a Pilot Study Rheumatology (Oxford, England). May, 2014 | Pubmed ID: 24390937 SSc causes intractable ischaemic ulcers. To avoid major amputation, we examined the safety and efficacy of therapeutic vascular angiogenesis for digital ulcers due to SSc.
Low-energy Extracorporeal Shock Wave Therapy Improves Microcirculation Blood Flow of Ischemic Limbs in Patients with Peripheral Arterial Disease: Pilot Study Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi. 2014 | Pubmed ID: 24614391 Because direct application of low-energy shock waves induces angiogenesis, we investigated the safety and efficacy of this new therapy to develop a noninvasive method of repeatable therapeutic angiogenesis for treating peripheral arterial disease (PAD).
Evaluation of Remodeling Process in Small-diameter Cell-free Tissue-engineered Arterial Graft Journal of Vascular Surgery. Apr, 2014 | Pubmed ID: 24745941 Autologous grafts are used to repair atherosclerotic cardiovascular diseases; however, many patients lack suitable donor graft tissue. Recently, tissue engineering techniques have emerged to make biologically active blood vessels. We applied this technique to produce arterial grafts using established biodegradable materials without cell seeding. The grafts were evaluated in vivo for vessel remodeling during 12 months.
Comparison of a Closed System to a Standard Open Technique for Preparing Tissue Engineered Vascular Grafts Tissue Engineering. Part C, Methods. May, 2014 | Pubmed ID: 24866863 We developed a prototype for a closed apparatus for assembling tissue engineered vascular grafts (TEVG) with the goal of creating a simple, operator-independent method for making TEVGs in order to optimize safety and enable widespread application of this technology. The TEVG is made by seeding autologous, bone marrow-derived mononuclear cells onto a biodegradable tubular scaffold and is the first man-made vascular graft to be successfully used in humans. A critical barrier, which has prevented the widespread clinical adoption of the TEVG, is that cell isolation, scaffold seeding, and incubation are performed using an open method. In order to reduce the risk of contamination, the TEVG is assembled in a clean room. Clean rooms are expensive to build, complex to operate, and are not available in most hospitals. In this investigation, we used an ovine model to compare the safety and efficacy of TEVGs created using either a standard density centrifugation-based open method or the new filter-based closed system. We demonstrated no graft-related complications and maintenance of growth capacity in TEVGs created using the closed apparatus. In addition, use of the closed system reduced the amount of time needed to assemble the TEVG by approximately 50%. Adaptation of similar methodologies may facilitate the safe translation and widespread use of other tissue engineering technologies.